XOMA Royalty Corp SEC Filings

XOMA Royalty Corp’s Chief Investment Officer Bradley Sitko reported equity holdings and a compensation-related share conversion. On the reported date, he exercised 3,737 Performance Stock Units (PSUs) at $0.00 per unit into 3,737 shares of common stock, increasing his directly held common stock to 82,961 shares. The filing shows he continues to hold 41,112 PSUs, which each represent a right to one share of common stock and vest only if the stock reaches specified price levels and he remains in service through each vesting date. The report also lists additional indirect holdings in common stock, preferred stock, and depositary shares held by his spouse, children, and a 401(k) plan.

XOMA Royalty Corp’s Chief Financial Officer Jeffrey Trigilio exercised 4,000 Performance Stock Units, converting them into 4,000 shares of common stock at an exercise price of $0.00 per share. Each PSU represents a contingent right to receive one share of common stock upon meeting specified stock price and service conditions.

To cover tax obligations related to this vesting, 1,632 common shares were disposed of at $36.76 per share through a tax-withholding transaction, which is not an open-market sale. After these transactions, Trigilio directly holds 92,368 shares of XOMA common stock and 26,000 Performance Stock Units.

XOMA Royalty Corp director Joseph M. Limber exercised stock options to acquire 3,026 shares of common stock at $11.20 per share. The options, which had been fully vested and exercisable since July 21, 2017, were fully exercised, leaving no remaining options from this grant. Following the exercise, he directly holds 9,234 shares of common stock, 20,000 depositary shares of 8.375% Series B cumulative stock, and 10,000 shares of 8.625% Series A cumulative perpetual preferred stock.

XOMA Royalty Corporation has called a virtual annual stockholder meeting for May 21, 2026, and is asking investors to vote on board elections, auditor ratification, equity plans and executive pay. Seven directors, including CEO Owen Hughes and independent chair Jack L. Wyszomierski, are nominated for one-year terms.

Stockholders are asked to ratify Deloitte & Touche as 2026 auditor, approve a 425,000-share increase to the 2010 Long Term Incentive and Stock Award Plan (about 2.5% dilution including 5,003,000 Series X convertible shares), adopt a new 2026 Employee Stock Purchase Plan for 500,000 shares, and give a non-binding say-on-pay vote on executive compensation.

XOMA Royalty Corp amendment: The Vanguard Group filed a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that led to disaggregated reporting by Vanguard subsidiaries.

The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The filing lists Vanguard's Malvern address and XOMA's principal office at 2200 Powell St, Emeryville, CA.

XOMA Royalty Corp director Jack L. Wyszomierski exercised stock options and increased his direct common share holdings. On March 24, 2026, he exercised a Stock Option for 3,026 shares at $11.20 per share, receiving the same number of Common Stock shares. Following the transaction, he directly owns 21,530 shares of XOMA Royalty Corp common stock. The option had been fully vested and exercisable since July 21, 2017, indicating a routine derivative exercise rather than an open-market purchase or sale.

XOMA Royalty Corporation reports on its 2025 performance as a diversified biotech royalty aggregator. The company now holds economic interests in over 120 assets, including seven commercial products and 14 late-stage programs, and focuses on non-dilutive funding of drug developers.

In 2025, XOMA received $33.6 million in commercial payments and $16.9 million from milestones and other fees, for total cash receipts of $50.5 million. Key commercial contributors included VABYSMO, OJEMDA, MIPLYFFA and IXINITY. DSUVIA revenue was minimal after Alora discontinued commercial sales and later withdrew the product due to manufacturing constraints.

The company expanded its portfolio through transactions such as the Takeda Revenue Share Agreement, Castle Creek’s D‑Fi royalty financing, and acquisitions of Pulmokine and LAVA, adding rights to multiple late‑stage and partnered programs. It also executed a stock repurchase program, buying 648,708 shares for $16.1 million by year-end, and operated with a lean team of 14 employees.

XOMA Royalty Corporation reported a strong turnaround for 2025, with income and revenues rising to $52.1 million from $28.5 million in 2024 and net income improving to $31.7 million from a net loss of $13.8 million.

Cash receipts reached $50.5 million, including $33.6 million in royalties and commercial payments and $16.9 million in milestones and fees, and the company generated positive cash flow from operations. XOMA deployed $25.0 million to acquire additional royalty and milestone assets and repurchased 648,048 common shares for $16.0 million.

At December 31, 2025, XOMA held cash and cash equivalents of $133.7 million, including $50.8 million in restricted cash, against long-term debt of $96.5 million. The portfolio expanded to more than 100 assets, with multiple commercial and late-stage programs supporting growing royalty streams.